ActiveSight has signed an expanded crystallography services agreement with Lexicon Pharmaceuticals, the medicinal chemistry division of Lexicon Genetics Incorporated (Nasdaq: LEXG).
The agreement covers co-crystallography services for multiple proprietary targets of Lexicon Pharmaceuticals and is the third agreement between the two companies.
According to Duncan McRee, President of ActiveSight:
"We are delighted that Lexicon Pharmaceuticals has decided to expand their relationship with ActiveSight. We look forward to providing continued structural biology support for Lexicon's drug discovery programs."Source: ActiveSight
Comment Preview